Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

202.08 +1.20 (+0.60%)
Official Closing Price Updated: 7:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
74 75 Next >
Stock(ing) Stuffers That Could Be Lovin The High 2024
Via Talk Markets
Healthcare Sector Stocks: Consistent Above-Average Growth And Income
The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records. 
Via Talk Markets
8 Analysts Have This to Say About AbbVie
Via Benzinga
Better Income Stock: AT&T or AbbVie?
These two blue chips are highly prized for their top-shelf dividend programs. 
Via The Motley Fool
3 of the Most Attractive Dividend Stocks in the Pharma Space
Discover the resilience and growth potential of pharma dividend stocks, offering stability and consistency in the healthcare sphere. 
Via InvestorPlace
Dividend Income Update For November 2023
It’s dividend income update time. This is one of my favorite times of the month, as I get to review the previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
Decoding AbbVie's Options Activity: What's the Big Picture?
Via Benzinga
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
These stocks could bring investors more than just a lump of coal for Christmas. 
Via The Motley Fool
Exposures Coal
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The 7 Most Undervalued Growth Stocks to Buy in December
Buy these distressed names now and ride their share prices higher over the coming year as they stage a comeback. 
Via InvestorPlace
Economic Safety Nets: 7 Defensive Stocks Providing Portfolio Stability
Although some signs of economic progress is seen, other signs suggest that investors should consider defensive stock picks. 
Via InvestorPlace
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to... 
Via Benzinga
Exposures Product Safety
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors
It's making a major acquisition to beef up a key area of its pipeline. 
Via The Motley Fool
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)  
Via Benzinga
AbbVie continues shopping spree with biotech buyout
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend. 
Via MarketBeat
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
The 3 Best Cheap Stocks to Buy in December
Investors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately. 
Via InvestorPlace
4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December
These companies offer above-average income streams that should continue rising. 
Via The Motley Fool
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
The big drugmaker went on a holiday shopping spree. 
Via The Motley Fool
3 Dividend Stocks You Can Safely Hold for Decades
These companies and their dividends are built to last. 
Via The Motley Fool
Better Dividend Stock: AbbVie vs. Medical Properties Trust
Which of these high-yield stocks has what it takes to keep raising their payouts? 
Via The Motley Fool
3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows
Buying these shares can provide you with some excellent recurring income while also diversifying your portfolio. 
Via The Motley Fool
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days. 
Via The Motley Fool
Healthcare Gems: 3 Essential Long-Term Stock Picks
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks. 
Via InvestorPlace
AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals
Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the... 
Via Benzinga
Why Cerevel Therapeutics Stock Is Higher
Cerevel Therapeutics Holdings, Inc. 
Via Benzinga
Why Methode Electronics Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings. 
Via Benzinga
Verint Reports Strong Earnings, Joins Semtech, Alphabet And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining more than 100 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.